CJC-1295 DAC

CJC-1295 is a synthetic analogue of growth hormone releasing hormone (GHRH) that increases plasma levels of growth hormone and insulin-like growth factor 1 (IGF-1). DAC is an additive moiety that prolongs the plasma half-life of CJC-1295.

CJC-1295 DAC is a modified version of the peptide CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog. The “DAC” stands for “dacarbazine,” a chemical that’s attached to modify the peptide.

**Key Characteristics of CJC-1295 DAC:**

* **Long Half-Life:** The key feature of CJC-1295 DAC is its significantly extended duration of action compared to standard GHRH or other growth hormone secretagogues. This is due to the dacarbazine modification, which reduces the rate of metabolism of the peptide in the body. The longer half-life leads to sustained release of growth hormone.

* **Growth Hormone Stimulation:** Like other GHRH analogs, CJC-1295 DAC aims to stimulate the pituitary gland to release growth hormone. It does this by mimicking the action of natural GHRH in the body.

* **Uses (primarily off-label):** CJC-1295 DAC, like other similar peptides, is often used in off-label contexts. These include:
* **Potential Anti-Aging Effects:** Claims exist about the potential to combat age-related decline and improve body composition. However, strong scientific evidence is lacking.
* **Muscle Growth and Recovery:** Some proponents assert that CJC-1295 DAC can improve muscle growth and recovery, leading to an improved physique. This is often marketed for athletic enhancement but lacks definitive clinical backing.
* **Metabolic Improvement:** Claims of improved metabolic function and body composition, similar to other GHRH analogs, are often made but need further scientific verification.

* **Important Considerations:**
* **Limited Clinical Data:** While some studies exist on various peptides with similar mechanisms, strong, conclusive evidence supporting the benefits of CJC-1295 DAC for most of the advertised applications is currently lacking.
* **Potential Side Effects:** As with other peptide therapies, potential side effects are possible, including, but not limited to, headaches, nausea, and others.
* **Regulation and Safety:** CJC-1295 DAC is often not regulated under standard drug approval processes for human use, and its use should be approached with caution. Its use outside of clinical settings is often unapproved and carries associated legal and safety risks.
* **Cost:** Such peptide products can be expensive.

* **In Summary:** CJC-1295 DAC is a modified peptide that aims to increase the duration of GH stimulation, purportedly leading to numerous benefits. However, robust evidence supporting its use for non-clinical, non-prescribed applications is still limited. Individuals considering its use should carefully weigh the potential benefits and risks in consultation with a healthcare professional. Its purported benefits in anti-aging or physique enhancement contexts are largely based on anecdotal evidence, not conclusive scientific data.

Context: Therapeutic use of GHRH to enhance GH secretion is limited by its short duration of action.

Objective: The objective of this study was to examine the pharmacokinetic profile, pharmacodynamic effects, and safety of CJC-1295, a long-acting GHRH analog.

Design: The study design was two randomized, placebo-controlled, double-blind, ascending dose trials with durations of 28 and 49 d.

Setting: The study was performed at two investigational sites.

Participants: Healthy subjects, ages 21-61 yr, were studied.

Interventions: CJC-1295 or placebo was administered sc in one of four ascending single doses in the first study and in two or three weekly or biweekly doses in the second study.

Main outcome measures: The main outcome measures were peak concentrations and area under the curve of GH and IGF-I; standard pharmacokinetic parameters were used for CJC-1295.

Results: After a single injection of CJC-1295, there were dose-dependent increases in mean plasma GH concentrations by 2- to 10-fold for 6 d or more and in mean plasma IGF-I concentrations by 1.5- to 3-fold for 9-11 d. The estimated half-life of CJC-1295 was 5.8-8.1 d. After multiple CJC-1295 doses, mean IGF-I levels remained above baseline for up to 28 d. No serious adverse reactions were